Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | ATF4 | P18848 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27716512 | 0.77 | PKM (0.36) | — | |
| SCHEMBL17527837 | 0.76 | ALDH1A1 (0.53) | ALDH1A1SMYD3YAP1TEAD4POLB | |
| SCHEMBL28626663 | 0.73 | EPHX1 (0.34) | ALDH1A1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL27746258 | 0.72 | EPHX1 (0.41) | ALDH1A1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL1787822 | 0.72 | EPHX1 (0.41) | ALDH1A1SMN1; SMN2EPHX2EPHX1 | |
| SCHEMBL2680036 | 0.72 | CNR1 (0.33) | EPHX2 | |
| SCHEMBL295416 | 0.72 | TP53 (0.47) | ALDH1A1SMYD3HTTSMN1; SMN2LMNA | |
| SCHEMBL28249232 | 0.71 | HRH3 (0.33) | EPHX1 | |
| SCHEMBL24549699 | 0.71 | ALDH1A1 (0.58) | ALDH1A1SMYD3YAP1TEAD4POLB | |
| SCHEMBL12847378 | 0.71 | ALDH1A1 (0.63) | ALDH1A1SMYD3YAP1TEAD4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | ALDH1A1 2617/4885SMYD3 2015/4885YAP1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.